Podcasts about antiretrovirals

Join PollyAnnamazing and her guest, viral TikTok Sexual Health Educator, Christopher Hetzer RN, MSN, as they discuss the ever evolving landscape HIV treatments.  Check out our conversations on the use of the antiretrovirals PEP and PrEP. This is Part 1 of a memorable conversation regarding responsible sex education and treatment for all humans so don't forget to  jump on board with Buried Pleaseures ! 

Episode Notes Drs. Emily Kirkpatrick, Paul Sax, and Jill Strayer join Dr. Rachel Britt to discuss their experiences using injectable long-acting antiretrovirals, especially cabotegravir/rilpivirine, in their clinics. Listen to learn not only about logistical challenges with these drugs, but also creative solutions to overcome them. Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/ Listen to Breakpoints on iTunes, Overcast, Spotify, Listen Notes, Player FM, Pocket Casts, Stitcher, Google Play, TuneIn, Blubrry, RadioPublic, or by using our RSS feed: https://sidp.pinecast.co/ Check out our podcast host, Pinecast. Start your own podcast for free with no credit card required. If you decide to upgrade, use coupon code r-7e7a98 for 40% off for 4 months, and support Breakpoints.

Editor's Summary by Kirsten Bibbins-Domingo, PhD, MD, MAS, Editor in Chief of JAMA, the Journal of the American Medical Association, for the January 3, 2023, issue. Related Content: Audio Highlights

In this episode, Cristina Mussini, MD, shares her approach to caring for aging patients with HIV. This includes not just focusing on their HIV, but their over well-being, such as:Maintaining a healthy weight, eating healthy and staying mobile Overcoming the obstacle of stigma from society and self-stigmaEmpowering patients to care for themselvesIn women who are often caregivers most of their life:Encouraging self-careStaying up to date with preventive care such as cancer screenings (eg, mammography, annual Pap smear, and colonoscopy)Teaching patients to love themselvesMaking sure the patient knows you truly care for themFaculty:Cristina Mussini, MDHead of Department of Infectious Diseases and Tropical MedicineFull Professor of Infectious DiseasesInfectious Diseases Clinics, University HospitalUniversity of Modena and Reggio EmiliaModena, ItalyLink to full program:https://bit.ly/3KkF4iZ

legacycares.orgfallingoutlgbtq.cominstagram: @fallingoutlgbtqpodtwitter: @fallinglgbtqMelissa Grove M.S., LPC has served as Executive Director of Legacy Counseling Center, Inc. since 1999, transforming the agency into the largest provider of mental health services for HIV+ people in the South. The Grace Project National Conference for Women Living with HIV she founded hosts 200 HIV+ women annually. Other projects include founding Legacy Founders Cottage, an AIDS care facility, and creating the centralized housing solution, Homebaseforhousing.org website. Her newest program, Legacy Master Leasing, sublets apartments to homeless people living with HIV. Ms. Grove speaks around the nation on issues pertaining to mental health, relationships, muscular dystrophy, HIV and chronic illness She additionally has a private therapy practice in Dallas, TX.She was named the 2014 Public Citizen of the Year through the North Central Texas National Association of Social Workers, and received the 2015 Black Tie Dinner Kuchling Humanitarian Award. Currently Ms. Grove has served on the National Consumer Advisory Committee for the Muscular Dystrophy Association and consults on the STS4HIV Project, a project of the National Institute on Drug Abuse.

Many drugs can interfere with antiretroviral therapy. Dhineli Perera chats with Yasmin Hughes, an advanced trainee in sexual health medicine, about the importance of checking potential interactions when prescribing other medicines.

We talk with Chloe Orkin, M.D., about one aspect of our future that in some very concrete ways has already arrived, and yet is currently out of reach for millions: long-acting medical interventions for HIV, the first of which were approved in the U.S. and Europe for treatment over a year ago and approved in the U.S. for prevention late last year. The beginning of the long-acting era has revealed anew some longstanding questions regarding who these drugs primarily benefit, who is able to receive them, and how our entire medical system is set up to serve -- or not serve -- the people who can most benefit from it.   Dr. Orkin is a professor of HIV medicine at Queen Mary University of London and the president of the Medical Women's Federation. She is one of world's leading minds in HIV research in medicine -- as well as one of the leading voices in conversations about health equity, access, and anti-discrimination.   Read the full transcript (clicking the link also helps support the podcast!): https://www.thebodypro.com/article/future-hiv-care-podcast-3-long-acting-antiretrovirals     Our podcast team: Episode host and executive producer Myles Helfand; audio producers/engineers Alex Portaluppi and Lucy Mueller; project manager Alina Mogollon-Volk; and podcast editors Maria Elena Perez and Juan Michael Porter II.

Can cancer immunotherapy help cure HIV? Find out about this and more in today's PV Roundup podcast.

Dr. Simmons is a clinician educator in the Section of Infectious Diseases and an Associate Program Director for the Internal Medicine Residency at Boston University, who joins us to speak about antiretrovirals for HIV!

Show notes at pharmacyjoe.com/episode619. In this episode, I'll discuss the management of antiretrovirals in critically ill patients. . The post 619: Management of Antiretrovirals in Critically Ill Patients appeared first on Pharmacy Joe.

Show notes at pharmacyjoe.com/episode619. In this episode, I ll discuss the management of antiretrovirals in critically ill patients. . The post 619: Management of Antiretrovirals in Critically Ill Patients appeared first on Pharmacy Joe.

Dr. Fidelia Bernice, Dr. Rodrigo Burgos, and Dr. Neha Pandit, join Breakpoints to discuss the first available long-acting antiretroviral agent, cabotegravir/rilpivirine. Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/

Kenya's running low on anti-HIV drugs. Antiretrovirals can be really helpful when it comes to keeping people living with HIV healthy. But for the last couple of months, they've been hard to come by in Kenya. This is partly due to a tax dispute between the government and donors who import the drugs. Health workers on the ground tell a different story though. Some say access to these life-saving drugs has been a problem for a while. So, how's this affecting the lives of the estimated 1.5- million Kenyans living with HIV? Hosted by Alan Kasujja (@Kasujja on Twitter) #AfricaDaily

Link to bioRxiv paper: http://biorxiv.org/cgi/content/short/2020.09.05.284422v1?rss=1 Authors: Smith, A. S., Ankam, S., Basa, R. C. B., Gordon, K. L., Terskikh, A. V., Jordan-Sciutto, K. L., Price, J., McDonough, P. M. Abstract: Combination antiretroviral therapy (cART) improves life expectancy and lowers the incidence of central nervous system (CNS) opportunistic infections, lymphomas, and HIV-associated dementia in HIV+ people. However, mild-to-moderate HIV-associated neurocognitive disorders (HAND) persist in about 50% of HIV+ people, even when HIV replication is well controlled. In vitro, animal model, and clinical studies suggest that cART neurotoxicity could be a contributing factor to the progression of HAND. In this study, we developed two in vitro model systems using glutamatergic neurons derived from human induced pluripotent stem cells (hiPSC-Gluts) and fetal neural precursor cells (hNPCs) to assay for antiretroviral (ARV) effects on mature and developing neurons, respectively. We tested four ARVs: the nucleoside/nucleotide reverse transcriptase inhibitors tenofovir disproxil fumarate (TDF) and emtricitabine (FTC) and the integrase inhibitors dolutegravir (DTG) and elvitegravir (EVG). DTG, EVG, and TDF decreased hiPSC-Glut viability and neurite length; all four antiretrovirals decreased hiPSC-Glut synapse counts; and DTG and EVG decreased the frequency and magnitude of hiPSC-Glut calcium transients. The magnitude of these neurotoxic effects increased with longer ARV exposure times and with the exposure of hiPSC-Gluts to two or three ARVs simultaneously. These results suggest that certain ARVs could cause HAND by decreasing the survival and function of CNS neurons. In fetal hNPCs, TDF decreased viability and changed the distribution of epigenetic histone modifications, suggesting that this ARV may alter neurogenesis, which could impair cognition in adults and/or CNS development for those exposed to ARV in utero or early childhood. Our study establishes human preclinical neurotoxicity systems that can screen for potential ARV CNS toxicity and develop safer cART regimens. Copy rights belong to original authors. Visit the link for more info

Presented by Geeta Gupta To earn ACCME or ACPE credit, go online to scientiacme.org/cmecoursecontent.php?ID=295 to view the slides and complete the post-test. In this online CME self-learning program: The development of antiretroviral therapy (ART) has had a dramatic impact on HIV-related morbidity and mortality. The use of ART in HIV-infected patients has been the core strategy to not only treat HIV but also prevent vertical HIV transmission. Antiretrovirals can be used for HIV prevention in patients who are not HIV-infected but are repeatedly exposed to HIV in a strategy termed pre-exposure prophylaxis (PrEP). Although the rationale for PrEP stems from successful HIV prevention in HIV exposed infants with the use of ART during labor, early post-partum period, and throughout breastfeeding, it has more recently applied to been applied to sexual transmission (e.g., people with multiple partners or HIV serodiscordant couples) and people who inject drugs illicitly with support from the literature. Because much of what comprises evidence and guidelines supporting PrEP has been published relatively recently and because healthcare professionals are oftentimes unable to keep up with the steady publishing of literature and evolution of clinical practice in a timely manner, continuing healthcare education activities in this area are warranted. This program is supported by an educational grant from Gilead. Faculty Disclosure: Dr. David J. Cennimo has no relevant financial relationships to disclose.  

Several observations suggest that retroviruses might be able to kill motor neurons, causing forms of ALS. Here we review these data, focusing on the theory that reactivation of an "endogenous" retrovirus we all have hiding in our genes called Herv-K might cause some cases of sporadic ALS. We examine drugs that attack retroviruses as potential treatments for patients with ALS.

Several observations suggest that retroviruses might be able to kill motor neurons, causing forms of ALS. Here we review these data, focusing on the theory that reactivation of an "endogenous" retrovirus we all have hiding in our genes called Herv-K might cause some cases of sporadic ALS. We examine drugs that attack retroviruses as potential treatments for patients with ALS.

Could planet Earth be a living creature, how do they name medicines, what's the difference between a heart attack and a cardiomyopathy, how do HIV protective drugs work and how were the Egyptian pyramids built? Plus, news of a new gene that could screen for heart disease. Like this podcast? Please help us by supporting the Naked Scientists

Could planet Earth be a living creature, how do they name medicines, what's the difference between a heart attack and a cardiomyopathy, how do HIV protective drugs work and how were the Egyptian pyramids built? Plus, news of a new gene that could screen for heart disease. Like this podcast? Please help us by supporting the Naked Scientists

Peter Piot outlines key themes and priorities emerging from The Lancet/UNAIDS Commission launched on June 25

Rafick-Pierre Sekaly discusses a Review about barriers to a cure for HIV.

Daniela de Angelis discusses HIV incidence in England and Wales among men who have sex with men.

April highlights, including discussion of a new antibiotic for C Difficile.

February highlights, including discussion of HIV therapy, rotavirus, polio vaccination, and surgery for drug-resistant TB.

Didier Raoult discusses optimum treatment for Q fever endocarditis.

Peter Hayward discusses highlights from the July HIV themed issue.

An expert view on TB/HIV co-infection from Linda-Gail Bekker.

Host Nicholas Fogelson discusses articles from The Green Journal from November and December of 2009.  Topics include Flu Vaccines and Antiretrovirals in Pregnancy, HPV Vaccine Safety in Pregnancy (yes), Moxibustion for Version (crazy), and Stupid Birth Control Comparisons (Pharma gone wild) Academic OB/GYN Episode 13 – Green Journal November-December 2009

Discussion of public awareness campaigns to prevent inappropriate use of antibiotics.

Audrey Ceschia discusses issue highlights, including impact of HIV infection on cancer risk.

Discussion of pandemic influenza H1N1, and antiretroviral therapy in low-income and middle-income countries.

July 24: experts review the International AIDS Society meeting.

Discussion of the malaria Special Report, and news from the International AIDS Society meeting in South Africa.

Discussion of the WHO Maximising Positive Synergies report concerning global health initiatives and health systems.

Laurent Lantieri discusses successful facial transplantation of a man with severe neurofibroma.

Chants from HIV activists, the launch of The Lancet HIV prevention series, and the voice of a former US President: a round-up of audio highlights from the XVII World AIDS meeting in Mexico City.

Pam Das and Sally Hargreaves discuss highlights from the July 26 issue of The Lancet and the August issue of The Lancet Infectious Diseases ahead of the World AIDS meeting in Mexico next month.

Pam Das and Sally Hargreaves discuss highlights from the August issue of The Lancet Infectious Diseases ahead of the World AIDS meeting in Mexico next month.

Dr Erika Sims from the University of East Anglia, UK, discusses the research article in this week's issue showing how newborn screening for cystic fibrosis is justifiable in economic terms, building on previous evidence showing the clinical value of newborn screening.

Pam Das And Richard Lane discuss the highlights from the November issue. The topics covered include treatment standards for tuberculosis, future possibilities for a vaccine against diseases caused by worm infestations.